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Abstract
Background: p27kip1 (p27) is a multifunctional protein implicated in regulation of cell cycling, signal transduction, and
adhesion. Its activity is controlled in part by Phosphatylinositol-3-Kinase (PI3K)/Akt1 signaling, and disruption of this
regulatory connection has been identified in human breast cancers. The serine/threonine protein kinase Akt1 directly
phosphorylates p27, so identifying the modified residue(s) is essential for understanding how it regulates p27 function.
Various amino acids have been suggested as potential targets, but recent attention has focused on threonine 157 (T157)
because it is located in a putative Akt1 consensus site. However, T157 is not evolutionarily conserved between mouse
and human. We therefore re-evaluated Akt1 phosphorylation of p27 using purified proteins and in cells.
Results: Here we show purified Akt1 phosphorylates human and mouse p27 equally well. Phospho-peptide mapping
indicates Akt1 targets multiple sites conserved in both species, while phospho-amino acid analysis identifies the targeted
residues as serine rather than threonine. P27 deletion mutants localized these sites to the N-terminus, which contains
the major p27 phosphorylation site in cells (serine 10). P27 phosphorylated by Akt1 was detected by a phospho-S10
specific antibody, confirming this serine was targeted. Akt1 failed to phosphorylate p27S10A despite evidence of a second
site from mapping experiments. This surprising result suggested S10 phosphorylation might be required for targeting the
second site. We tested this idea by replacing S10 with threonine, which as expected led to the appearance of phospho-
threonine. Phospho-serine was still present, however, confirming Akt1 sequentially targets multiple serines in this region.
We took two approaches in an attempt to explain why different residues were previously implicated. A kinetic analysis
revealed a putative Akt1 binding site in the C-terminus, which may explain why mutations in this region affect p27
phosphorylation. Furthermore, commercially available recombinant Akt1 preparations exhibit striking differences in
substrate specificity and site selectivity. To confirm S10 is a relevant site, we first showed that full-length wild type Akt1
purified from mammalian cells phosphorylates both human and mouse p27 on S10. Finally, we found that in cultured cells
under physiologically relevant conditions such as oxidative stress or growth factor deprivation, endogenous Akt1 causes
p27 accumulation by phosphorylating S10.
Conclusion: Identifying where Akt1 phosphorylates p27 is essential for understanding its functional implications. We
found that full-length wild type Akt1 – whether purified, transiently overexpressed in cells, or activated in response to
cellular stress – phosphorylates p27 at S10, a noncanonical but evolutionarily conserved site known to regulate p27
activity and stability. Using recombinant Akt1 recapitulating this specificity, we showed modification of p27S10 also leads
to phosphorylation of an adjacent serine. These results integrate PI3K/Akt1 signaling in response to stress with p27
regulation through its major phosphorylation site in cells, and thus identify new avenues for understanding p27
deregulation in human cancers.
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Background
Information transmitted by signaling pathways deter-
mines whether a cell continues the proliferative cycle or
adopts an alternative fate. This decision requires regulat-
ing Cyclin Dependent Kinases (CDKs), which are acti-
vated by phosphorylation and temporal association with
a unique cyclin subunit (D, E or A type in G1/S phase)
[reviewed in [1]]. Two families of CDK inhibitory proteins
(CKIs) have been identified: INK4 proteins (p15, p16,
p18 and p19) specifically inhibit cyclin D-CDK4/6, while
Cip/Kip proteins (p21, p27, and p57) are considered
more broad-spectrum inhibitors of cyclin D, E, and A
CDK complexes [2,3].
P27 regulation is particularly important because it func-
tions as a tumor suppressor that is often disrupted in
human cancers, usually by compromising its stability
and/or location [4-7]. Consistent with this view mice
without p27 develop pituitary tumors and display
increased susceptibility to carcinogens [8-10]. Mice lack-
ing a single copy of the p27 gene are still hypersensitive to
carcinogens, illustrating the importance of precisely con-
trolling its levels and activity [11,12]. Despite these obser-
vations the role of p27 in tumorigenesis remains
enigmatic due to its multifunctionality. Although first
characterized as a CDK inhibitor that negatively regulates
cell cycle progression [13-16], p27 also possesses CDK-
independent functions such as inhibiting the adaptor pro-
tein GRB2 (to regulate signaling) or targeting RhoA (to
regulate adhesion) [17-19]. Disrupting these p27 activi-
ties could also contribute to the disease state, especially
given recent evidence cancer cells do not necessarily
require hyperactive CDKs [20,21].
P27 multifunctionality also likely explains its complex
regulation. The protein contains distinct cyclin and CDK
binding sites at its N-terminus, a C-terminus motif
responsible for interacting with RhoA, a proline rich
domain for binding GRB2 (aa 90–95), and a bipartite
nuclear localization signal (NLS; aa 162–176)
[3,19,22,23] (Figure 1). Posttranslational modifications
like phosphorylation regulate p27 activity by modulating
p27 is highly conserved between human and mouse Figure 1
p27 is highly conserved between human and mouse. Comparison of human and mouse p27 sequences reveals they are 
92% identical. Highlighted amino acids show absolute differences. Underlined amino acids indicate functional motifs: Cyclin E 
(RXL), CDK2 (FNF), Grb2 (PXXP) binding sites and the bipartite Nuclear Localization Signal (aa 152–166). Solid arrows show 
conserved phosphorylation sites. Blow up of Akt1 consensus site shows T157 is not maintained between species.
 Grb2 Binding Site
hp27:
1MSNVRVSNG S
10    PSLERMDARQ      AEHPKPSACR      NLFGPVDHEE      LTRDLEKHCR      DMEEASQRKW
60
mp27:
1MSNVRVSNG S
10    PSLERMDARQ      AEHPKPSACR      NLFGPVNHEE      LTRDLEKHCR      DMEEASQRKW
60
hp27:
61NFDFQNHKPL        EGKYEWQEVE KGSLPEFYYR      PPRPPKGACK     VPAQESQDVS      GSRPAAPLIG
120
mp27:
61NFDFQNHKPL        EGRYEWQEVE RGSLPEFYYR      P PRPPKSACK      VLAQESQDVS      GSRQAVPLIG
120
hp27:
121APANSEDTHL       VDP KTDPSDS QTGLAEQCAG I RKRPATDDS      STQNKRANRT      EENVSDGSPN
180
mp27:
121SQANSEDRHL       VDQMPDSSDN PAGLAEQCPG MRKRPAAEDS      SSQNKRANRT      EENVSDGSPN
180
hp27:
181AGSVEQT
187PKK   PGLRRRQT
198
mp27:
181AGTVEQT
187PKK   PGLRR–QT
197
Akt consensus site: R X R X X T/S
hp27:   R K R P A T
157
mp27:  R K R P A A
157
 Cyclin Binding Site
 CDK Binding Site
 Nuclear Localization SignalCell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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its levels, location, and/or association with binding part-
ners. Cyclin E-CDK2 phosphorylates p27 at threonine
187 (T187) in late G1 phase, initiating p27 ubiquitination
and proteasomal degradation [24-27]. Serine 10 (S10)
appears to be the major site of p27 phosphorylation in
cells, and is targeted by several kinases including Map
kinase, a recently identified mitogen responsive kinase
called hKIS, and possibly Akt1 [28-30]. S10 modification
stabilizes p27 and promotes its nuclear export via the car-
rier protein CRM1, thereby alleviating cyclin-CDK inhibi-
tion and perhaps initiating p27 cytoplasmic functions
[31,32]. A better understanding of what kinase(s) target
S10 would provide much needed insight into the physio-
logical relevance of modifying this residue.
The PI3K/Akt1 pathway plays a key role in cell survival
and proliferation by modulating gene expression, protein
synthesis, and cell cycle machinery [33]. PI3K regulates
p27 function via a multi-pronged effort that includes
altering p27 transcription, protein levels, and location
[34,35]. Akt1 contributes to this process by phosphorylat-
ing and inhibiting Forkhead transcription factors that pro-
mote p27 transcription [36]. In addition, Akt1 directly
phosphorylates p27 in order to alter its levels and/or loca-
tion in the cell [30,37-42]. Thus, inappropriate PI3K/Akt1
activation could contribute to cellular transformation in
part by deregulating p27 [35]. Identifying the p27 resi-
due(s) phosphorylated by Akt1 is essential for determin-
ing their regulatory significance. Numerous sites have
Akt1 phosphorylates human and mouse p27 Figure 2
Akt1 phosphorylates human and mouse p27. A, Purification of His-tagged p27 from E. coli. Upper panel: Aliquots from 
indicated steps of the purification protocol (see Methods) were separated by SDS-PAGE and visualized by Coomassie blue 
staining. Bottom panel: Indicated forms of His-tagged p27 were purified as described in Methods and their concentration com-
pared by SDS-PAGE followed by Coomassie staining. B, Constitutively active Akt1 phosphorylates p27 lacking T157. An in 
vitro kinase assay was performed as described in the Methods by incubating commercial recombinant Akt1(prep1) (see Meth-
ods) and [32P]ATP with the indicated substrates. Samples were then separated by SDS-PAGE and visualized by autoradiogra-
phy. Lane 1 is a negative control lacking Akt1 substrate, while lane 2 shows Akt1 phosphorylates its well-known substrate GSK. 
Lane 3–5 show Akt1 phosphorylates human wild type p27, mouse p27, and hp27T157A equally well.
B. A.
His-p27
p27 WB
Autoradiograph
    1         2          3       4  5
Akt-1         +    +          +         +      +
GSK         -    +          -          -      -
hwtp27         -    -           +         -      -
mp27         -    -           -          +      -
hp27T157A      -    -           -          -      +Cell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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Akt1 phosphorylates p27 at multiple serines within the N-terminus Figure 3
Akt1 phosphorylates p27 at multiple serines within the N-terminus. A, Phospho-peptide maps comparing hwtp27 to 
hp27T157A. The kinase assay was performed as described with indicated forms of p27. After SDS/PAGE separation (upper 
panel) radiolabeled p27 was subjected to two-dimensional phospho-peptide analysis (lower panel) (See Methods for details). 
Direction of electrophoresis and chromatography are indicated by arrows. B, Schematic representation of phospho-peptide 
pattern. Ellipses 1–3 correspond to phospho-peptides in 3A, while number 4 represents [32P]. C, Akt1 phosphorylates p27 at 
serines. Radiolabeled human wtp27 was hydrolyzed to constituent amino acids and then separated by electrophoresis on a 
TLC plate as described in Methods. Top panel: scheme representing migration of the phospho-amino acid standards (phospho-
S and phospho-T). Middle panel: Phospho-amino acid standards separated by electrophoresis and visualized by 0.25% ninhydrin 
(see Methods). Bottom panel: phospho-amino acid analysis of [32P]hwtp27 visualized by phosphoimager. D, Akt1 phosphor-
ylates p27(1–86). Kinase assay was performed as described with His-purified p27(1–86) and p27(87–198). Samples were sepa-
rated by SDS/PAGE and visualized by autoradiography. Commassie staining shows the levels of deletion mutants were similar. 
E, Phospho-peptide maps comparing hwtp27 to hp27(1–86). Radiolabeled hwtp27 and p27(1–86) were analyzed as in A.
A.
C.
B.
TLC
(-)     Electrophoresis    (+)
1
2
3
4
D.
 1-86  87-198
Coomassie
Stain E.
Standards
[
32P]-aa from hwtp27
(-)  Electrophoresis (pH 1.9)  (+)
p-S p-T Origin
Human wt p27 p27 (1-86)
(-) Electrophoresis    (+)
TLC
1-86 WT
[
32P]p27
[
32P]p27 (1-86)
Human wt p27 Human p27T157A
(-) Electrophoresis    (+)
TLC
 T157A WT
[
32P]p27
     1 2       3      4  5
Akt1          +      +       -          +         -
GSK          +      -        -          -          -
p27(87-198)      -      +       +         -          -
p27(1-86)          -      -        -          +     +
AutoradiographCell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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been proposed, but recent attention has focused on thre-
onine 157 (T157). This residue is located in an Akt1 con-
sensus sequence "RKRPAT157" within the p27 NLS.
Recombinant Akt1 failed to phosphorylate a p27 mutant
lacking this site, and in some breast cancer cell lines Akt1
hyperactivation altered p27 location [39-42].
Important p27 phosphorylation sites are usually con-
served among species (e.g. T187 and S10), but T157 is an
alanine in the mouse. This observation prompted us to re-
evaluate the site(s) targeted by Akt1. We now show puri-
fied Akt1 phosphorylates mouse and human p27 equally
well. Phospho-peptide and phospho-amino acid analysis
revealed Akt1 modifies neighboring serine residues that
are conserved among species. Analysis of p27 deletion
mutants localized these residues to the N-terminus 1–86
amino acids, which contain the well known S10 phospho-
rylation site. We confirmed Akt1 phosphorylates S10 by
western blot using an antibody specific for phospho-S10.
Surprisingly, Akt1 failed to phosphorylate p27S10A
despite mapping evidence indicating existence of an addi-
tional site. This suggested S10 phosphorylation might be
a pre-requisite for its modification. We confirmed this
idea using a p27 mutant containing threonine in place of
S10, which now resulted in both radiolabeled threonine
and serine. Our data indicate Akt1 sequentially phospho-
rylates multiple serine residues within a conserved but
non-canonical region, one of which (S10) has already
been identified as a major regulator of p27 function.
These results were confirmed in cultured cells where co-
expressing Akt1 with p27 leads to an increase in S10 phos-
phorylation. Finally, we show that stressing tissue culture
cells with oxidative insult or growth factor deprivation
causes an Akt-dependent increase in p27S10 phosphor-
ylation.
Results
Akt1 phosphorylates both human and mouse p27
Numerous reports indicate Akt1 directly phosphorylates
human p27 [30,37-42]. Several potential sites have been
suggested, based mainly on the failure of Akt1 to phos-
phorylate purified p27 containing site specific mutations
[30,39-42]. A threonine located at position 157 of human
p27 recently emerged as a leading candidate, in part
because it resides within an Akt1 consensus sequence
(RXRXXT157). If this residue is targeted then Akt1 should
not radiolabel mouse p27 (which contains alanine at
position 157) or human p27 in which T157 has been
mutated to alanine. To test these predictions we estab-
lished an in vitro kinase assay similar to that employed by
other groups [39-41]. It utilizes recombinant, constitu-
tively active Akt1 obtained from a commercial supplier
(see Methods), and His-tagged forms of p27 purified from
E. coli. The upper panel of Figure 2A is a Coomassie
stained gel showing a typical purification profile of
human His-tagged p27, while the lower panel compares
the purified forms of p27 utilized in subsequent assays.
Mouse p27 is easily identified because it migrates slightly
faster than the human version. Purified Akt1 was incu-
bated with its well characterized substrate GSK (positive
control) or the different p27s in the presence of [32P]-γ-
ATP. Consistent with earlier reports recombinant Akt1
phosphorylated both GSK and human p27 (Figure 2B;
lanes 2 and 3). However, Akt1 also phosphorylated
mouse p27 and p27T157A to a similar extent (Figure 2B;
lanes 4 and 5), suggesting Akt1 targets a site(s) other than
T157.
Akt1 phosphorylates p27 at multiple serines
To determine if Akt1 phosphorylates p27 at multiple sites,
we generated a phospho-peptide map by digesting radi-
olabeled p27 with trypsin and separating the resulting
peptides in two dimensions. A single site should corre-
spond to a single radiolabeled peptide. Conversely, if
mutating T157 to alanine alters specificity then the phos-
pho-peptide pattern should change. We therefore com-
pared phospho-peptide maps for human wild type p27
and the p27T157A mutant. After the kinase assay [32P]p27
was separated by SDS-PAGE and transferred to PDVF
membrane. It was then excised and subjected to tryptic
digestion. Resulting peptides were separated by high volt-
age electrophoresis followed by ascending chromatogra-
phy as described in Methods. The phospho-peptide maps
of wtp27 and p27T157A are identical, indicating the same
site(s) are targeted (Figure 3A). The maps clearly show
three prominent radiolabeled spots of varying intensity.
Their orientation is depicted in Figure 3B, while the fourth
spot is inorganic phosphate and thus serves as an internal
control. Phospho-peptides 1 and 2 are lying in a diagonal
characteristic of phospho-isomers (variable number of
phosphates on the same peptide) [43]. Identity of the less
intense spot 3 is unclear. It may result from partial diges-
tion or phosphorylation of a less efficiently targeted resi-
due located on a different peptide.
Table 1: Tryptic peptides for Human p27Kip1
Peptides Position
MSNVR 1–5
VSNGSPSLER 6–15
QAEHPKPSACR 20–30
DMEEASQR 51–58
GSLPEFYYRPPRPPK 82–96
VPAQESQDVSGSR 101–113
PAAPLIGAPANSEDTHLVDPK 114–134
TDPSDSQTGLAEQCAGIR 135–152
PATDDSSTQNK 155–165
TEENVSDGSPNAGSVEQTPK 170–189
QT 197–198Cell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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Six tryptic peptides from p27 contain multiple serine and/
or threonine residues (Table 1). We therefore performed a
phospho-amino acid analysis to determine whether Akt1
targets serine, threonine or both. Surprisingly, Akt1 phos-
phorylated hwtp27 predominantly on serine (Fig 3C).
Because multiple serine residues are located on peptides
throughout p27, we utilized deletion mutants to deter-
mine if Akt1 phosphorylates the N- or C-terminus.
Recombinant Akt1 phosphorylated p27(1–86) but not
p27(87–198) (Figure 3D; compare lanes 2 and 4). To rule
out the possibility Akt1 specificity was altered by the dele-
tion, we performed phospho-peptide analysis of (1–86)
and full length p27. The maps are identical (Figure 3E),
indicating Akt1 phosphorylates multiple serines located
between amino acids 1–86.
Akt1 phosphorylates serine 10
The predicted tryptic digest shows only one N-terminus
peptide containing two serines (Table 1; amino acids 6–
15). Our attention was immediately drawn to S10 –
despite the fact it is not within an Akt1 consensus motif –
because it is a well known, physiologically relevant p27
phosphorylation site. To determine if S10 is one of the
sites targeted by Akt1 we utilized a commercially available
antibody directed against p27 phosphorylated at this loca-
tion. This antibody clearly recognizes p27 only after incu-
bation with Akt1 in a kinase reaction (Figure 4A). In
contrast, it failed to recognize p27S10A whether or not
Akt1 was present. To further confirm that the S10 anti-
body is recognizing phosphorylated p27, products of the
kinase reaction were incubated alone or in the presence of
alkaline phosphatase (Figure 4B). As expected, the signal
was significantly diminished after phosphate removal.
Serine 10 and surrounding amino acids are conserved in
both mouse and human p27 (Figure 1), and we con-
firmed Akt1 targets S10 in mouse p27 using the same
methodology (Figure 4C; lanes 3 and 4). Furthermore,
phospho-peptide maps of mouse p27 were identical to
Akt1 phosphorylates p27S10 Figure 4
Akt1 phosphorylates p27S10. A, Determination of S10 phosphorylation by specific antibody. Recombinant Akt1 was incu-
bated with the indicated forms of His-tagged p27 in the presence of non-labeled ATP. Samples were separated by SDS/PAGE 
and analyzed by western blot with the indicated antibodies. B, Alkaline phosphatase abolishes recognition of phosphorylated 
p27. hwtp27 was phosphorylated as in A and treated with or without alkaline phosphatase. Samples were then analyzed by 
western blot with the indicated antibodies. C, Akt1 phosphorylates serine 10 in mouse p27. Akt1 was incubated alone or with 
the indicated forms of p27 in the presence of non-labeled ATP. Total and phospho-S10 levels were analyzed by western blot as 
indicated. D, Phospho-peptide maps of human and mouse p27. Radiolabeled samples were analyzed as described in Figure 3A.
B. A.
C.
   1         2         3      4
Phospho-p27S10
Total p27
Akt1 +        -      +  +
hwtp27 -         +      +  -
mp27 -         -      -  +
D.
Phospho-p27S10
Total p27
Akt
Akt1           +        -          +      -
hwtp27           +        +          -      -
hp27S10A          -        -          +      +
     1  2     3 4
Phospho-p27 S10
Total p27
Phospho-p27     +       +
Phosphatase     -       +
TLC
Human wt p27 Mouse p27
(-) Electrophoresis    (+)
mp27 hp27
[
32P]p27Cell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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Akt1 sequentially phosphorylates p27 at S10 and a neighboring serine Figure 5
Akt1 sequentially phosphorylates p27 at S10 and a neighboring serine. A, Akt1 does not phosphorylate hp27S10A. 
Upper panel: Recombinant Akt1 was incubated in a kinase reaction with the indicated forms of p27 as described. Samples were 
separated by SDS/PAGE and visualized by autoradiography. Bottom panel: His-tagged cyclin-E-CDK2 was purified from trans-
fected HEK293 cells (see Methods), then incubated with indicated forms of p27 in the presence of [32P]-γ-ATP. Samples were 
separated by SDS-PAGE and visualized by autoradiography. Commassie staining shows equal amounts of hwtp27 and p27S10A 
were present in the reactions. B, Akt1 phosphorylates hp27S10T. Kinase reaction was performed with recombinant Akt1 and 
indicated substrates. Upper panel: autoradiograph showing phosphorylated p27. Bottom panel: western blot showing similar 
levels of p27 in the reaction. C, Phospho-amino acid analysis comparing hwtp27 and hp27S10T. Kinase reaction described in B 
was repeated and radiolabeled p27 was subjected to PAA as in Figure 3C. Top panel: scheme representing migration of phos-
pho-amino acid standards. Second panel: Phospho-amino acid standards separated by electrophoresis and visualized by 0.25% 
ninhydrin. Third panel: phospho-amino acid analysis of radiolabeled hwtp27. Bottom panel: phospho-amino acid analysis of 
hp27S10T. Radiolabeled peptides and amino acids were detected by phosphoimager.
[
32P]p27
Akt1          +      - +         -
hwtp27          +      + -          -
hp27S10A        -      - +         +
CycE/CDK2      +              +
hwtp27          +              -
hp27S10A        -              +
[
32P]p27
p27 Coomassie Stain
 1         2        3  4          5
p27 WB
[
32P]p27
Akt          +     -          +        -     +
hwt p27          +     +         -         -     -
hp27S10T         -     -          +        +     -
hp27S10A         -     -          -         -     +
[
32P]-aa from hp27S10T
Standards
[
32P]-aa from hwtp27
(-)  Electrophoresis (pH 1.9)  (+)
p-S p-T Origin
B.
C.
A.Cell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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Kinetic analysis of p27 phosphorylation Figure 6
Kinetic analysis of p27 phosphorylation. A, Time course of p27 phosphorylation. Kinase reaction was performed as 
described with hwtp27 or p27T157A and stopped at indicated times. Phosphorylation is shown by autoradiograph and total 
p27 by western blot. The amount of [32P] incorporated was measured by densitometry, expressed as OD, and plotted vs. reac-
tion time. [32P] incorporation was normalized against the highest value arbitrarily set at 1. B, Phosphorylation rate as a function 
of p27 concentration. Indicated dilutions of hwtp27 and p27T157A were utilized in the kinase reaction. Autoradiographs show 
[32P] incorporation. Graph shows radiolabeled p27 quantitated as in A vs. protein dilution. C, Rate of S10 phosphorylation. Indi-
cated forms of His-tagged p27 were incubated with Akt1 and non-labeled ATP. Samples were separated by SDS-PAGE and vis-
ualized by western blotting with the indicated antibodies. D, p27(87–198) inhibits Akt1 phosphorylation of p27. Kinase reaction 
was performed with hwtp27, Akt1 and [32P]-γ-ATP in the presence of indicated amounts of p27(87–198). Upper panel: autora-
diograph. Bottom panel: western blot showing levels of full length and C-terminus of p27. E, p27(87–198) inhibits Akt1 phos-
phorylation of p27S10. Kinase reaction was performed as described in D with non-labeled ATP in the presence of p27(87–198) 
or GSK. S10 phosphorylation was determined by western blot analysis.
Protein Dilution
[
32P]p27T157A
[
32P]hwt27
1/25      1/5       1
Time (min)      0 5         15       30 60
[
32P]p27T157A
[
32P]hwtp27
Total p27 WB
Total p27 WB
hwtp27 p27T157A
Phospho-p27S10
p27
Akt         +        +  +  +         +       +
A.
0
10
20
30
40
50
0.00 0.20 0.40 0.60 0.80 1.00
Protein Dilution
O
D
hwtp27
p27T157A
0
10
20
30
40
50
02 04 0 6 0
Time (min)
O
D
hwtp27
p27T157A
B.
C.
E.
D.
p27(87-198)    -
Akt1        +    + +
hwtp27        +    + +
[
32P]p27
p27 WB
p27(87-198) WB
Phospho-p27S10
Total p27
    1         2          3       4
Akt         +   +          +        +
hwtp27         -   +          +        +
p27(87-198)     -   -           +        -
GSK         -   -           -         +Cell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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that of the human protein, confirming the same sites are
phosphorylated in both species (Figure 4D).
P27S10 phosphorylation is required to target a second site
Phospho-peptide mapping suggests Akt1 targets multiple
sites (Figure 3A). Thus, we expected that mutating S10 to
alanine would not completely ablate p27 phosphoryla-
tion. Surprisingly, however, Akt1 failed to radiolabel
hp27S10A (Figure 5A, top panel). To rule out the possibil-
ity p27S10A was misfolded or otherwise compromised, a
kinase reaction was carried out using cyclin E-CDK2 puri-
fied from HEK293 cells as described in Methods. Both
hp27 and hp27S10A were phosphorylated equally well by
cyclin E-CDK2 (Figure 5A, middle panel) suggesting
Commercial recombinant Akt preparations show different specificity Figure 7
Commercial recombinant Akt preparations show different specificity. A, S10 phosphorylation by recombinant 
Akt1(prep2; see Methods). Recombinant Akt1(prep2) was incubated with His-tagged p27 in the presence of non-labeled ATP. 
Akt inhibitor was added where indicated. Samples were separated by SDS/PAGE and analyzed by western blot with the indi-
cated antibodies. B, Radiolabeled phosphate incorporation by Akt1(prep2). Reaction was carried out as described in Methods. 
Autoradiograph shows phosphorylation of GSK, hwtp27 and p27S10A. C, Akt1(prep2) lacks specificity. Kinase reaction as 
described in B was performed in the presence or absence or bovine serum albumin (BSA). Autoradiograph shows Akt1(prep2) 
phosphorylates BSA as well as p27. D, Radiolabeled phosphate incorporation by Akt1(prep3). Kinase reaction performed as in 
B with recombinant Akt1(prep3; see Methods). E, Phospho-amino acid analysis of hwtp27 and p27S10A phosphorylated by 
Akt1(prep3). Phosphorylated p27 was subjected to PAA as described in Methods. Upper panel: schematic representation of 
phospho-amino acid migration. Middle panel: PAA corresponding to hwtp27. Bottom panel: PAA corresponding to p27S10A.
A. B.
C.
Akt1(prep 3)     + +    +
GSK         + -     -
hwtp27         - +    -
p27S10A         - -     +
[
32P] BSA
 Autoradiograph
Akt1(prep 2)     +   +         +         +
hwtp27         -   +         -         +
BSA         +   +         -         -
[
32P]p27
[
32P]BSA & [
32P]Akt
Akt1(prep 2)        +       +      +      +
GSK             -       +      -      -
hwtp27             -       -      +      -
p27S10A             -       -      -      +
Autoradiograph
D.
E.
Akt1(prep2)      -      +        +        +
hwtp27          +      -         +        +
Akt-Inhibitor      -      -         -         +
Phospho-p27S10
p27
Akt1
    1          2         3      4
[
32P]-aa from hp27S10A
[
32P]-aa from hwtp27
 p-S p-T Origin
(-)       Electrophoresis        (+)Cell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
Page 10 of 18
(page number not for citation purposes)
hp27S10A structure is not dramatically disrupted. These
results not only confirm Akt1 targets S10, but also suggest
its modification is required for targeting another serine.
We directly tested this idea by taking advantage of the fact
Akt1 is a serine/threonine kinase. If S10 alone is phospho-
rylated then converting it to threonine should only gener-
ate radiolabeled phospho-threonine. However, if an
additional serine is also targeted both phospho-threonine
Full length Akt1 phosphorylates p27 at serine 10 in vitro and in cells Figure 8
Full length Akt1 phosphorylates p27 at serine 10 in vitro and in cells. A, Expression and activation of Akt1 in HEK293 
cells. Increasing amounts of HA-tagged wtAkt1 were transfected in HEK293 cells as described in the Methods. After 36 hours 
active and total levels of Akt1 were determined by western blot analysis. B, Full length wild type Akt1 phosphorylates p27. 
Overexpressed HA-Akt1 was purified by immunoprecipitation (IP-Akt1) and incubated alone or with indicated forms of His-
p27 in the presence of [32p]-γ-ATP as described in Methods. Autoradiograph shows full length Akt1 phosphorylates human and 
mouse p27 as well as the hp27T157A mutant. C, Wild type Akt1 targets S10. The kinase reaction was performed by incubating 
IP-Akt1 with non-radiolabeled ATP and indicated substrates. Western blot shows full length Akt phosphorylates S10. D, Spe-
cific Akt inhibitor blocks S10 phosphorylation. A kinase reaction was performed as in C incubating full length His-purified Akt1 
with p27 in the presence or absence of Akt inhibitor. S10 phosphorylation was determined by phospho-specific antibody. E, 
Full length Akt1 fails to phosphorylate hp27S10A. Full length His-Akt1 was incubated in a kinase reaction with the indicated 
forms of p27 in the presence of radiolabeled ATP. Samples were separated by SDS/PAGE and visualized by autoradiography. 
Akt inhibitor was added where indicated.
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Stress-activated Akt phosphorylates p27 at serine 10 in cells Figure 9
Stress-activated Akt phosphorylates p27 at serine 10 in cells. A, Overexpressed Akt1 phosphorylates S10 in HEK293 
cells. hwtp27 was transiently overexpressed in HEK293 alone or in the presence of co-transfected Akt1. S10 phosphorylation 
was determined by western blot analysis after 36 hrs. B, CuSO4-dependent activation of Akt leads to p27S10 phosphorylation. 
Cells were transiently transfected as in A and treated with vehicle or CuSO4 for 2 hours prior to harvest. Samples were ana-
lyzed by western blot. Akt inhibitor was added 30 minutes prior to CuSO4. C, Endogenous Akt1 activated by oxidative stress 
phosphorylates p27S10. HEK293 cells were transfected with p27 and treated with CuSO4 or FBS for 2 hours prior to harvest. 
Inhibitors were added 30 minutes before treatment. Samples were analyzed by western blot. D, H2O2-activated endogenous 
Akt phosphorylates p27S10. Experiment was performed as in C treating the cells with H2O2. E, Growth factor withdrawal leads 
to an Akt-dependent phosphorylation of p27S10. Hela cells were grown in 10% FBS (prolif.) or serum starved (G0) in the pres-
ence or absence of Akt inhibitor. Cells were harvested and phosphorylation of S10 analyzed by western blot. F, Mitogen-acti-
vated Akt does not target p27S10. HDF cells were synchronized in G0 by serum deprivation and re-fed with 20% FBS. Cells 
were lysed at the indicated time points and analyzed by western blot.
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and phospho-serine should be present. We generated a
p27S10T mutant by site-directed mutagenesis. Akt1 still
phosphorylated hp27S10T, albeit more weakly than wild
type p27 (Figure 5B, compare lanes 1 and 3). Neverthe-
less, the amounts were sufficient for phospho-amino acid
analysis. As shown previously Akt1 phosphorylated wild
type p27 almost exclusively on serines (Figure 5C, third
panel). In contrast, p27S10T clearly shows both phospho-
serine and phospho-threonine (Figure 5C, bottom panel).
These results provide further evidence Akt1 targets S10,
and reveal existence of a second modified serine. Because
p27S10A is not radiolabeled by Akt (see Figure 5A and B),
we conclude that modification of the second site is
dependent on first phosphorylating S10. This scenario
could also explain why the second site appears to be phos-
phorylated less efficiently.
Kinetic analysis of p27 phosphorylation
Given our extensive evidence Akt1 phosphorylates multi-
ple serines within the N-terminus, it is unclear why previ-
ous studies implicated other residues. A limitation of
identifying phosphorylation sites solely by mutational
analysis is the potential for indirect effects (e.g. overall
protein structure can be compromised, or an enzyme
binding site can be ablated). In the case of p27 several of
the previously identified Akt1 targets localize to the C-ter-
minus, so their mutation might disrupt an Akt1 binding
region that alters phosphorylation of N-terminus serines.
To test this idea we analyzed kinetics of hwtp27 and
p27T157A phosphorylation. Figure 6A shows the rate of
p27T157A phosphorylation is similar to that of wild type.
Since excess p27 could obscure differences in binding
affinity that affect the rate, we repeated the analysis at var-
ious p27 concentrations. Rates were again similar, sug-
gesting mutation of T157 does not dramatically affect
Akt1 association with p27 (Figure 6B). Similar results
were obtained when looking specifically at S10 phospho-
rylation using the phospho-p27S10 antibody (Figure 6C).
Even though mutating T157 to alanine had no obvious
effect on p27 phosphorylation, other residues in the C-ter-
minus might still be involved in Akt1 binding. We
addressed this question by determining if p27(87–198)
can inhibit phosphorylation of the full length protein.
Recombinant Akt1 was incubated with [32P]-γ-ATP and
full length p27 in the presence of increasing C-terminus.
Figure 6D shows phosphorylation of hwtp27 was dimin-
ished when p27(87–198) was present. Similar results
were obtained when the outcome was measured using the
phospho-specific S10 antibody (Figure 6E). Thus, muta-
tions in the p27 C-terminus could conceivably compro-
mise an Akt1 binding site and affect phosphorylation at
N-terminal residues. Although we were unable to demon-
strate this consequence when T157 was mutated in our
system, alteration of this site might affect p27 phosphor-
ylation under different reaction conditions.
Purified preparations of recombinant Akt1 show different 
specificities
A survey of the literature revealed that putative Akt1 phos-
phorylation sites in p27 have been identified using similar
in vitro kinase assays. However, in most cases the purified
recombinant Akt1 was obtained from various commercial
suppliers, and how it was activated, produced, and puri-
fied is different. We therefore analyzed activity of addi-
tional commercially available Akt1 preparations to
determine if they yielded similar results. A carboxy-termi-
nal His-tagged Akt1 (Akt1-prep2) phosphorylated
p27S10 as indicated by the phospho-specific S10 anti-
body (Figure 7A). This reaction was largely inhibited by
an Akt inhibitor, suggesting S10 was modified by Akt
rather than a contaminating kinase. However, when we
repeated the reaction using [32P]-γ-ATP, we were surprised
to discover that in contrast to our earlier results Akt1-
prep2 also phosphorylated p27S10A (Figure 7B). We
noted that Akt1-prep2 appeared to lack specificity, as it
efficiently phosphorylated BSA to the same extent as p27
(Figure 7C). Similar results were obtained with another
recombinant Akt1 sample (Akt1-prep3: truncated, puri-
fied from insect cells and activated using PDK1) (Figure
7D), and in this case threonine in p27 was the main target
(Figure 7E). These observations could explain why differ-
ent p27 residues have been identified as targets for Akt1.
Our initial analysis was also carried out using purified
active Akt1 obtained from a commercial supplier. We
were fortunate, however, in that this preparation displays
greater specificity for physiologically relevant substrates
and does not phosphorylate BSA (Figure 2B). Although
these observations suggest S10 is likely a physiologically
relevant site, to further resolve this issue we analyzed p27
phosphorylation by wild type full length Akt1.
Full length Akt1 from mammalian cells phosphorylates 
serine 10 in vitro
We first repeated the in vitro kinase assay using full length
wild type Akt1 purified from mammalian cells. HEK293
cells were transfected with increasing amounts of a plas-
mid containing HA-tagged Akt1 under control of the CMV
promoter. Equal amounts of cell extract (as determined by
Bradford assay) were then subjected to western blot anal-
ysis. Figure 8A shows HA-tagged Akt1 was overexpressed
and activated in HEK293 cells. We therefore repeated the
transfection and purified HA-Akt1 by immunoprecipita-
tion with an HA antibody (IP-Akt1). Figure 8B shows full
length Akt1 phosphorylates hwtp27, mp27 and
p27T157A, similar to results obtained in our initial anal-
ysis with recombinant enzyme (Figure 2B). Furthermore,
in all cases full length wild type Akt1 phosphorylated S10
as indicated by western blotting with the phospho-specificCell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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antibody (Figure 8C). To rule out the possibility another
kinase co-precipitated with HA-Akt or was nonspecifically
pulled down by the antibody, we overexpressed His-
tagged Akt1 in HEK293 cells, purified it on a Nickel col-
umn, and performed a kinase assay with non-labeled ATP.
His-Akt phosphorylated p27 at S10 as determined by
phospho-specific S10 antibody (Figure 8D, lane 3) and
the reaction was inhibited by an Akt inhibitor (Figure 8D,
compare lanes 3 and 4). To confirm S10 is the major site
we looked for incorporation of radiolabeled phosphate
onto p27S10A. Figure 8E shows His-Akt phosphorylates
hwtp27 and that this reaction is blocked by Akt inhibitor
(compare lanes 3 and 2). In contrast, His-Akt completely
fails to phosphorylate p27S10A (lane 4).
Stress activated Akt phosphorylates p27S10 in cultured 
cells
Given the strong evidence that Akt1 phosphorylates p27
at S10 in vitro, we sought to determine if Akt1 also targets
this site in cells. We first simply overexpressed p27 in
HEK293 cells alone or co-transfected with Akt1. After 36
hours cells were harvested and analyzed for p27S10 phos-
phorylation by western blot. The amount of S10 phos-
phorylated p27 significantly increased in the presence of
Akt1, consistent with our in vitro data indicating Akt1 tar-
gets this site (Figure 9A).
Akt is activated in response to a variety of different stimuli
such as growth factors or cellular stress (50–53). Oxida-
tive stress via exposure to copper was previously shown to
activate Akt (50), so we examined whether treating cells
with CuSO4  had an effect on p27 phosphorylation.
Indeed, incubation of HEK293 cells overexpressing p27
and Akt1 with CuSO4 resulted in higher levels of p27S10
phosphorylation (Figure 9B, compare lanes 3 and 4).
Total p27 levels also increased as expected given previous
work showing S10 modification stabilizes p27 (28).
Importantly, pre-treatment of cells with Akt inhibitor
totally abolished S10 phosphorylation, indicating the
CuSO4 effect was mediated by Akt1 (Figure 9B, lane 5). To
determine if endogenous Akt targets p27S10 in response
to stress, HEK293 cells were transfected with p27 alone
and then treated with CuSO4. Exposure to CuSO4 again
caused an increase in p27S10 phosphorylation (Figure
9C, compare lanes 2 and 3) which was abolished by pre-
treating cells with wortmannin or Akt inhibitor (Figure
9C, compare lane 3 to lanes 4 and 5). As expected we
observed increased levels of total p27 due to the increased
stability of the S10 phosphorylated form (Figure 9C, mid-
dle panel).
To confirm that CuSO4 treatment was activating Akt1 via
generation of reactive oxygen species (ROS), we repeated
the experiment with H2O2  (51). H2O2  treatment of
HEK293 cells overexpressing p27 with increased p27S10
phosphorylation, which was inhibited by pre-incubating
cells with wortmannin or Akt inhibitor (Figure 9D). In
marked contrast, mitogen stimulation also leads to
increased Akt1 activation and p27S10 phosphorylation
(Figure 9C). However, in this case it is not prevented by
the Akt inhibitor or wortmannin. These results suggest
Akt1 specifically phosphorylates p27 at S10 in response to
cellular stress, while a different kinase carries out this
modification in response to mitogens.
Previous analysis of p27S10 phosphorylation in cells
revealed it increases in response to the stress of mitogen
withdrawal. To determine if Akt1 is responsible we ana-
lyzed p27 phospho-S10 levels after serum starving Hela
cells in the absence or presence of Akt inhibitor. Serum
starvation increases p27S10 phosphorylation, and this
effect is dramatically blocked by Akt inhibitor (Figure 9E).
These results strongly suggest Akt is largely responsible for
phosphorylating p27S10 in response to mitogen removal.
In contrast, mitogen stimulation of serum-starved cells
also leads to Akt1 activation, but as predicted above this
does not correlate with nor lead to increased p27S10
phosphorylation (Figure 9F). These results suggest that
although Akt1 is activated in response to a variety of stim-
uli, it specifically phosphorylates p27S10 when cells are
exposed to cellular stresses such as reactive oxygen species
or growth factor deprivation.
Discussion
Previous work has clearly demonstrated that Akt1 phos-
phorylates p27 [30]. Due to the multifunctionality and
complex regulation of p27, determining the physiological
significance of this event would be greatly facilitated by
precisely identifying the targeted residue(s). Akt1 is a ser-
ine/threonine kinase, so there are 27 potential targets in
human p27 (18 serines and 9 threonines). Several resi-
dues throughout the polypeptide chain have been postu-
lated as Akt1 targets (S10, T157, T187, T198, or
combinations thereof), based mainly on deletion and
mutation analysis using purified proteins and commercial
recombinant Akt1 [30,39-42]. This methodology has
proven effective at identifying physiologically relevant
phosphorylation sites in many different proteins, includ-
ing p27. For instance, cyclin E-CDK2 phosphorylation of
p27T187 was initially revealed by this approach [24].
However, its relative ease and simplicity compared to
more labor intensive techniques like peptide mapping is
tempered by potential indirect effects (e.g. mutating a
binding rather than phosphorylation site).
Recent attention has focused on p27T157 because of its
location within a putative RXRXXT157 Akt1 consensus site
located within the p27 NLS (Figure 1) [39-42]. T157 is not
present in mouse p27, however, which is curious given
that both p27 and the PI3K/Akt1 pathway are highly con-Cell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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served in the two species. This lack of conservation is in
marked contrast to other physiologically relevant p27
phosphorylation sites such as T187 and S10. Nonetheless,
there is precedence for nonconservation of sites with other
Akt1 substrates. For example, Akt1 blocks apoptosis by
phosphorylating human caspase-9 within the
"RXRXXS196" consensus site even though S196 is not
present in mouse and dog [44,45].
To try and resolve these issues we re-examined p27 phos-
phorylation by Akt1. Our results show that Akt1 phospho-
rylates human p27, mouse p27, and human p27T157A
equally well. Phospho-peptide mapping of p27 revealed
three radiolabeled spots, two of which lie in a diagonal
characteristic of the same peptide containing different
amounts of phosphate [43]. The less intense third spot
may represent a partial digestion product that can arise
when two basic amino acids (e.g. positions 15 and 19 in
p27) are in the same vicinity [43]. Alternatively, the third
spot might represent a less efficiently targeted residue
residing on a different peptide. Phospho-amino acid and
deletion analysis revealed that phosphate is incorporated
almost exclusively into N-terminus serines. Our attention
was immediately drawn to S10 for three reasons: 1) It is
located in the only N-terminus tryptic peptide containing
multiple serines (Table 1); 2) It has been previously iden-
tified as a major site of p27 phosphorylation in cells [28];
and 3) S10 was previously suggested as a potential Akt1
phosphorylation site [30]. A commercially available
phospho-S10 antibody specifically recognized both
mouse and human p27 after pre-incubation with Akt1
and ATP, confirming at least one of the modified residues
is S10. Because phospho-peptide mapping indicated a sec-
ond serine is located on the same peptide, it could be
either S7 or S12. Experiments are currently underway to
precisely identify this site, which is complicated by its
close proximity to S10 and the sequential nature of the
reaction.
We generated hp27S10A with the expectation it would
still be phosphorylated by Akt1 at the second site. How-
ever, the kinase completely failed to radiolabel this
mutant, suggesting S10 modification is a pre-requisite for
targeting the other residue. We attempted to mimic S10
phosphorylation by changing it to glutamic acid, but Akt1
did not label this mutant (data not shown). As an alterna-
tive approach we changed S10 to threonine. A kinase
assay confirmed p27S10T is still phosphorylated, and
phospho-amino acid analysis now revealed both radiola-
beled threonine and serine. These results confirmed Akt1
phosphorylates S10, and showed its modification is
required for targeting the second serine. Phospho-S10
could alter p27 structure to reveal the second site, perhaps
involving the proline at position 11. Akt1's ability to
sequentially target multiple residues in p27 raises the
interesting possibility a similar mechanism occurs at the
previously identified RXRXXS/T consensus site, which
might have been overlooked by mutational analysis.
The region surrounding S10 is not the typical Akt1 con-
sensus site (RXRXXS/T) originally characterized using a
panel of purified peptides [46]. S10 is immediately adja-
cent to Pro11, and the peptide analysis suggested such a
configuration is not targeted by Akt1 [46]. Obviously,
however, the structure or recognition of an isolated pep-
tide may be quite different within the context of a larger
amino acid sequence. Thus, our results hint at the exist-
ence of a novel sequence motif that might be utilized in
other Akt1 substrates. A blast search using a possible motif
derived from the p27S10 region (RXSXXS/TPSXXR) iden-
tified several proteins involved in the PI3K/Akt1 pathway
(e.g. Actin-binding LIM protein 1, PP2A, ABL1 and eIF4E
binding protein). It will be of interest to determine if any
of these potential candidates are phosphorylated by Akt1.
Why has there been so much confusion surrounding iden-
tity of the p27 residues(s) targeted by Akt1? One possible
complication is pointed out by our observation that while
Akt1 phosphorylates the N-terminus, it can also bind the
C-terminus. Depending upon the experimental system
and reaction conditions, mutations in this region could
inhibit phosphorylation of the N-terminal residues. Such
a situation is not unprecedented given that cyclin E-CDK2
binds p27 at the N-terminus region yet phosphorylates
T187 [24]. Likewise, another candidate for S10 phospho-
rylation (hKIS) was originally identified by its affinity for
the C-terminus portion of p27 [29]. The confusion could
also be explained by the use of different recombinant Akt1
preparations, which we found display varying specificity
towards potential substrates. These differences could arise
due to a contaminating kinase, or more interestingly as a
result of mutations introduced into Akt to facilitate its
activation and/or purification. Regardless, our observa-
tions suggest caution is warranted when using recom-
binant Akt1 to characterize substrate specificity. For this
reason and to confirm S10 is a relevant site, we analyzed
p27 phosphorylation by full length wild type Akt1 in vitro
and in cells. In both cases we found that Akt phosphor-
ylates p27 at serine 10.
Many different stimuli activating Akt1 have been identi-
fied. We found that two well characterized types of cellu-
lar stress known to activate Akt1 – reactive oxygen species
and growth factor withdrawal – also caused an increase in
p27 phosphorylation at S10. Furthermore, pre-treating
cells with small molecule inhibitors of Akt activation or
activity blocked this stress dependent increase in S10
phosphorylation.Cell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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This effect appears to be quite specific, as mitogen stimu-
lation also resulted in Akt1 activation but did not lead to
an increase in S10 modification. Akt activation in
response to stress is known to initiate a pro-survival
response, and p27S10 phosphorylation/stabilization
could play a role in this process by blocking cell cycle pro-
gression and/or modulating signal transduction pathways
[18,19]. These possibilities must be tempered by our
observation that when targeting S10 Akt1 can also phos-
phorylate a neighboring serine, which could have unex-
pected consequences or alter regulatory events typically
associated with S10 modification. Given our in vitro anal-
ysis suggesting Akt1 specificity can vary, it remains possi-
ble that Akt1 targets p27 residues other than/in addition
to S10 in response to different physiological conditions.
Regardless, our observation that Akt1 phosphorylates
p27S10 in response to cellular stress has important impli-
cations for current efforts to understand how PI3K/Akt1
normally regulates p27, as well as how this process is dis-
rupted in human cancers.
Conclusion
Akt1 phosphorylates p27 to regulate its activity, but the
identity of targeted residue(s) remains controversial. Here
we show that full-length wild type Akt1 – either purified
or in cells – phosphorylates p27 at S10, a noncanonical
but evolutionarily conserved site known to regulate p27
function. Using recombinant Akt1 that recapitulates this
specificity, we showed modification of p27S10 also leads
to phosphorylation of an adjacent serine. Although Akt1
is activated by many different stimuli, we found that it
specifically phosphorylates p27S10 in response to cellular
stress such as reactive oxygen species or growth factor dep-
rivation. These results integrate PI3K/Akt1 signaling with
p27 regulation through its major phosphorylation site in
cells, and thus identify new avenues for understanding its
deregulation in human cancers.
Methods
Protein expression constructs
P27, His-tagged Akt1, His-tagged cyclin E and CDK2 were
cloned into the CS2+ mammalian expression vector in
which protein production is driven by the CMV promoter
[24]. HA-tagged Akt1 was a gift of Dr. Richard Nho. Tags
are located at the N-terminus. For bacterial expression p27
was cloned into a Pet16B vector [24]. P27 mutants were
generated using the QuickChange site-directed mutagene-
sis kit (Stratagene, La Jolla, CA) and confirmed by DNA
sequencing.
Recombinant proteins and protein purification
Purified GSK protein was purchased from Cell Signaling
Technology. Purified recombinant Akt1 protein was
obtained from Cell Signaling Technology (prep1:#7502;
and prep3: #9274) and from Calbiochem (prep2). His-
tagged p27 was purified from E. coli extracts by Ni2+-affin-
ity chromatography. Briefly, the BL21 strain of E. coli was
transformed with Pet16B expression vectors containing
the cDNA of interest, grown to an OD of 0.6, and protein
synthesis induced by 1 mM IPTG for 4 hours. Cells where
lysed in non-denaturing buffer pH8 (50 mM NaH2PO4,
300 mM NaCl, 10 mM Imidazole, 0.05% tween) and His-
tagged proteins purified under native conditions accord-
ing to the manufacturer's directions using Ni-NTA kit
(QIAGEN). Purified proteins were dialyzed against 10
mM Tris pH8.0, 1 mM EDTA, 20 mM NaCl, 2 mM DTT
and 10% glycerol for 16 hours. P27 concentration was
determined by the Bradford method and comparison with
a known standard (BSA; BioRad) by Coomassie staining.
His-tagged cyclin E-CDK2, full length His-tagged Akt1 and
full length HA-tagged Akt1 were purified after transient
overexpression in HEK293 cells. Cells were harvested
under native conditions in non-denaturing buffer pH8.
Full length His-tagged Akt1 and His-tagged cyclin E-CDK2
were purified by incubating whole-cell extract with Ni2+-
agarose beads (QIAGEN) for 1 hour at 4°C. Beads were
washed 3 times with 1 ml of the above lysis buffer con-
taining 20 mM Imidazole, then once with kinase reaction
buffer (25 mM Tris pH7.5, 5 mM β-glycerophosphate, 2
mM DTT, 50 nM Na3VO3, 5 mM MgCl2, and 0.2 mg/ml
BSA). Full length HA-Akt1 was purified by immunopre-
cipitation with an antibody against HA-Tag (Santa Cruz,
Santa Cruz, CA) using protein A-agarose (Roche) as
described previously [22]. The kinase reaction was per-
formed as described below.
Kinase assays
Akt1 or cyclin E-CDK2 were incubated with purified His-
tagged p27 in a final volume of 20 μL containing 20 μM
non-labeled ATP (Sigma-Aldrich), 4 μCi [32P]-γ-ATP
(ICM), and kinase reaction buffer (25 mM Tris pH7.5, 5
mM β-glycerophosphate, 2 mM DTT, 5 μM Na3VO3, 5
mM MgCl2, and 0.2 mg/ml BSA). Reactions were per-
formed at 30°C for 60 min (unless otherwise indicated)
and quenched by addition of SDS sampler buffer. Sam-
ples were heated at 90°C for 5 minutes, centrifuged at
13000 rpm for 3 minutes, and separated by SDS-PAGE.
Proteins were then transferred to a PDVF membrane and
incorporation of radiolabel visualized by autoradiogra-
phy or phosphoimager.
Phospho-peptide and phospho-amino acid analysis
Phospho-peptide (PPA) and phospho-amino acid (PAA)
analysis were performed as described by Boyle et al. [43].
Briefly, kinase products were separated by SDS-PAGE and
transferred to PDVF membrane. Bands containing the
radiolabeled protein were visualized by autoradiography.
For PPA, proteins were eluted by soaking excised mem-
brane in 0.5% polyvinylpyrrolidone (PVP-360; Sigma)
plus 100 mM acetic acid at 37°C for 30 minutes to blockCell Division 2006, 1:11 http://www.celldiv.com/content/1/1/11
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nonspecific absorption of trypsin. The membrane was
then washed with water and 50 mM ammonium bicarbo-
nate. Radiolabeled proteins were digested by incubation
with 10 μg of trypsin in 50 mM ammonium bicarbonate
at 37°C for 2 hours, followed by a second incubation with
an additional 10 μg of trypsin overnight at 37°C. Phos-
pho-peptides were spotted on cellulose-TLC plates and
electrophoresed at 1500 V for 25 minutes. After air drying
the plates were placed in a chromatography tank contain-
ing isobutyric acid buffer (1250 ml isobutyric acid, 38 ml
n-Butanol, 96 ml pyridine, 58 ml glacial acetic acid, 558
ml water). Ascending chromatography was performed for
12 hours perpendicular to the direction of electrophore-
sis. Peptide maps were visualized by exposing plates to the
phosphoimager. To determine identity of phosphorylated
amino acids (PAA), bands containing radiolabeled pro-
teins were hydrolyzed with 6N HCl at 100°C for 1 hour
followed by lyophilization with a vacuum centrifuge. Dry
pellets were resuspended in pH1.9 buffer containing 1 μg
of nonlabeled phospho-serine and phospho-threonine
standards. Because Akt1 is a serine threonine protein
kinase it was not necessary to look for phospho-tyrosine,
which allowed us to run electrophoresis in one dimen-
sion. Samples were spotted on TLC plates and electro-
phoresed at 1500 V for 25 minutes. Phospholabeled
amino acids were visualized by exposing plates to the
phosphoimager. Standards were visualized by 0.25% nin-
hydrin in acetone spraying and 15 minute incubation at
65°C.
Cell culture
HEK293 and Human Diploid Fibroblasts (HDF) cells
were obtained from ATCC and cultured in Dulbecco's
Modified Eagle's Medium (DMEM) (GIBCO) supple-
mented with 10% (v/v) fetal bovine serum (FBS) (Atlas
Biologicals) at 37°C in 5% CO2. Hela cells were obtained
from Dr. Anja Bielinsky (University of Minnesota) and
cultured in DMEM (1 mg/ml glucose) (Cellgro) supple-
mented with 10% (v/v) FBS (Atlas Biologicals). Mitogen
deprivation was performed by growing cells to confluency
and removing FBS for 48 hours. Cells were then stimu-
lated with 20% FBS for the indicated times. When treating
cells with CuSO4, DMEM was removed, cells were washed
with PBS and incubated for 2 hours in Hanks' balanced
salt solution (HBSS) containing CuSO4. Where indicated,
cells were pre-treated with 200 nM wortmannin (Calbio-
chem) or 1 μM Akt inhibitor VIII (Calbiochem #124108)
for 30 minutes, washed with PBS, and then incubated in
HBSS containing CuSO4 and inhibitors.
Transient transfections
Transfections were performed using the calcium-phos-
phate precipitation method as described previously [24].
Briefly, indicated amounts of plasmids containing the
cDNA of interest were diluted in 500 μL calcium-phos-
phate solution, then added to 60 mm cell culture plates
containing proliferating HEK293 cells in 3 mL of DMEM
with 10% FBS. After 12 hours cells were washed with PBS
and allowed to recover for 24 hours in DMEM plus 10%
FBS prior to harvesting in indicated buffer. H2O2 was
added to transfected cells for 2 hours prior to harvest.
Where indicated, cells were pre-treated with 200 nM wort-
mannin (Calbiochem) or 1 μM Akt inhibitor VIII (Calbi-
ochem #124108) for 30 minutes prior to H2O2 addition.
In the case of CuSO4 treatment DMEM was removed, then
cells were washed with PBS and incubated for 2 hours in
Hanks' balanced salt solution (HBSS) containing CuSO4.
Where indicated cells were pre-treated with 200 nM wort-
mannin (Calbiochem) or 1 μM Akt inhibitor VIII (Calbi-
ochem #124108) for 30 minutes, washed with PBS, and
then incubated in HBSS containing CuSO4 and inhibitors.
Western blotting
Purified proteins or whole cell extracts were resolved by
SDS-polyacrylamide gel electrophoresis (PAGE), trans-
ferred to PDVF membranes, and visualized by immunob-
lotting with indicated antibodies. Bound antibodies were
detected using horseradish peroxidase-linked anti-mouse
or anti-rabbit antibodies (Amersham Pharmacia Biotech),
and visualized by enhanced chemiluminescence (Santa
Cruz) followed by exposure to X-ray film (Kodak X-Omat
AR). The antibodies employed are: anti-Akt1 and anti-
phospho-AktS473 (Cell Signaling Technology); anti-p27
(Transduction Labs); anti-phospho-p27S10 and anti-HA-
tag (Santa Cruz).
Alkaline phosphatase treatment
After the kinase reaction utilizing non-labeled ATP, phos-
phorylated p27 was incubated for 1 hour at 30°C in the
presence of 40 units of calf intestinal alkaline phosphatase
(Promega) in 20 μL of buffer containing 50 mM Tris-HCl
(pH 8.0) and 1 mM MgCl2. The reaction was stopped by
adding SDS-sample buffer and then subjected to SDS-
PAGE, followed by western blot analysis of total and S10
phosphorylated p27.
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